nach oben

Erschienen in:

01.02.2021 | MAGNETIC RESONANCE IMAGING

Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey

verfasst von: Domenico Albano, Alessandro Stecco, Giuseppe Micci, Luca Maria Sconfienza, Stefano Colagrande, Alfonso Reginelli, Roberto Grassi, Alessandro Carriero, Massimo Midiri, Roberto Lagalla, Massimo Galia

Erschienen in: La radiologia medica | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To perform a survey among all members of the Italian Society of Medical and Interventional Radiology (SIRM) to assess how whole-body MRI (WB-MRI) is performed in oncologic patients in Italy.

Methods

On March 2019, we administered an online poll to all SIRM members about their use of WB-MRI in 2018 asking 15 questions regarding oncologic indications, imaging protocol, use of contrast media, experience in WB-MRI, duration of scan time and reporting time.

Results

Forty-eight members participated to the survey. WB-MRIs/total MRIs ratio was 1%. Lymphoma was the most common indication (17/48, 35%), followed by myeloma and prostate cancer, with these three tumors representing the most common indication in 39/48 of cases (81%). WB-MRI acquisition time and reporting time were 46–60 min in 22/48 centers (46%) and 20–30 min in 19/48 (40%), respectively. WB-MRIs were mostly performed in 1.5T scanners (43/48, 90%), with surface coils (22/48, 46%) being preferred to Q-body (15/48, 31%) and integrated coils (11/48, 23%). Contrast media were injected in 22/48 of the centers (46%), mainly used for breast cancer (13/22, 59%). DWI was the most used sequence (45/48, 94%), mostly with b800 (27/48, 56%), b0 (24/48, 50%) and b1000 (20/48, 42%) values. In about half of cases, radiologists started evaluating WB-MRI non-contrast morphologic sequences, then checking DWI and post-contrast images.

Conclusion

WB-MRI was mainly performed at 1.5T unit, with lymphoma, myeloma and prostate cancer having been the most common indications. The extreme variability in the choice of imaging protocols and use of contrast agents demonstrates the need of a standardization of WB-MRI application in clinical practice.

Chien SH, Liu CJ, Hu YW et al (2015) Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study. Int J Cancer 137:658–665. https://doi.org/10.1002/ijc.29433CrossRefPubMed

Huang B, Law MW, Khong PL (2009) Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 251:166–174. https://doi.org/10.1148/radiol.2511081300CrossRefPubMed

Lauenstein TC, Semelka RC (2006) Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging 24:489–498. https://doi.org/10.1002/jmri.20666CrossRefPubMed

Galia M, Albano D, Narese D et al (2016) Whole-body MRI in patients with lymphoma: collateral findings. Radiol Med 121:793–800. https://doi.org/10.1007/s11547-016-0658-xCrossRefPubMed

Petralia G, Padhani AR, Pricolo P et al (2019) Whole-body magnetic resonance imaging (WB-MRI) in oncology: recommendations and key uses. Radiol Med 124:218–233. https://doi.org/10.1007/s11547-018-0955-7CrossRefPubMed

Albano D, Patti C, Lagalla R, Midiri M, Galia M (2017) Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma. J Magn Reson Imaging 45:1082–1089. https://doi.org/10.1002/jmri.25439CrossRefPubMed

Kwee TC, Takahara T, Ochiai R et al (2009) Whole-body diffusion-weighted magnetic resonance imaging. Eur J Radiol 70:409–417. https://doi.org/10.1016/j.ejrad.2009.03.054CrossRefPubMed

Albano D, La Grutta L, Grassedonio E et al (2016) Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: what radiologists should know. Magn Reson Imaging 34:922–931. https://doi.org/10.1016/j.mri.2016.04.023CrossRefPubMed

Xu GZ, Li CY, Zhao L, He ZY (2013) Comparison of FDG whole-body PET/CT and gadolinium-enhanced whole-body MRI for distant malignancies in patients with malignant tumors: a meta-analysis. Ann Oncol 24:96–101. https://doi.org/10.1093/annonc/mds234CrossRefPubMed

10.

Li B, Li Q, Nie W, Liu S (2014) Diagnostic value of whole-body diffusion-weighted magnetic resonance imaging for detection of primary and metastatic malignancies: a meta-analysis. Eur J Radiol 83:338–344. https://doi.org/10.1016/j.ejrad.2013.11.017CrossRefPubMed

11.

Dimopoulos MA, Hillengass J, Usmani S et al (2015) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol 20(33):657–664. https://doi.org/10.1200/JCO.2014.57.9961CrossRef

12.

Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis Reporting and Data System for Prostate Cancer: practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol 71:81–92. https://doi.org/10.1016/j.eururo.2016.05.033CrossRefPubMedPubMedCentral

13.

https://docs.google.com/forms/. Accessed 28 April 2019

14.

Silvestri E, Barile A, Albano D et al (2018) Interventional therapeutic procedures in the musculoskeletal system: an Italian Survey by the Italian College of Musculoskeletal Radiology. Radiol Med 123:314–321. https://doi.org/10.1007/s11547-017-0842-7CrossRefPubMed

15.

Sconfienza LM, Albano D, Messina C, Silvestri E, Tagliafico AS (2018) How, When, Why in Magnetic Resonance Arthrography: an International Survey by the European Society of Musculoskeletal Radiology (ESSR). Eur Radiol 28:2356–2368. https://doi.org/10.1007/s00330-017-5208-yCrossRefPubMed

16.

Albano D, Patti C, La Grutta L et al (2016) Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 85:313–318. https://doi.org/10.1016/j.ejrad.2015.12.006CrossRefPubMed

17.

Stecco A, Buemi F, Quagliozzi M et al (2015) Staging of primary abdominal lymphomas: comparison of whole-Body MRI with diffusion-weighted imaging and (18)F-FDG-PET/CT. Gastroenterol Res Pract 2015:104794. https://doi.org/10.1155/2015/104794CrossRefPubMedPubMedCentral

18.

Mayerhoefer ME, Karanikas G, Kletter K et al (2014) Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 20:2984–2993. https://doi.org/10.1158/1078-0432.CCR-13-3355CrossRefPubMed

19.

Albano D, Patti C, Matranga D, Lagalla R, Midiri M, Galia M (2018) Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: predictive role before treatment and early assessment after two courses of ABVD. Eur J Radiol 103:90–98. https://doi.org/10.1016/j.ejrad.2018.04.014CrossRefPubMed

20.

Mayerhoefer ME, Karanikas G, Kletter K et al (2015) Evaluation of diffusion-weighted magnetic resonance imaging for follow-up and treatment response assessment of lymphoma: results of an 18F-FDG-PET/CT-controlled prospective study in 64 patients. Clin Cancer Res 21:2506–2513. https://doi.org/10.1158/1078-0432.CCR-14-2454CrossRefPubMed

21.

Latifoltojar A, Punwani S, Lopes A et al (2019) Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin’s lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT. Eur Radiol 29:202–212. https://doi.org/10.1007/s00330-018-5445-8CrossRefPubMed

22.

Littooij AS, Kwee TC, de Keizer B et al (2015) Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: a prospective multicenter study. J Magn Reson Imaging 42:1646–1655. https://doi.org/10.1002/jmri.24938CrossRefPubMed

23.

Galia M, Albano D, Tarella C et al (2018) Whole body magnetic resonance in indolent lymphomas under watchful waiting: the time is now. Eur Radiol 28:1187–1193. https://doi.org/10.1007/s00330-017-5071-xCrossRefPubMed

24.

Albano D, Patti C, La Grutta L et al (2017) Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP. Eur Radiol 27:2129–2136. https://doi.org/10.1007/s00330-016-4535-8CrossRefPubMed

25.

Stecco A, Buemi F, Iannessi A, Carriero A, Gallamini A (2018) Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma. Leuk Lymphoma 12:1–11. https://doi.org/10.1080/10428194.2018.1434881CrossRef

26.

Kwee TC, Basu S, Torigian DA, Nievelstein RA, Alavi A (2012) Evolving importance of diffusion-weighted magnetic resonance imaging in lymphoma. PET Clin 7(1):73–82. https://doi.org/10.1016/j.cpet.2011.11.001CrossRefPubMed

27.

Adams HJA, Kwee TC, Vermoolen MA et al (2013) Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET. Eur Radiol 23:2271–2278. https://doi.org/10.1007/s00330-013-2835-9CrossRefPubMed

28.

Albano D, Patti C, Midiri M, Galia M (2018) Osteonecrosis in Hodgkin lymphoma treated by BEACOPP. Intern Med J 48:747–748. https://doi.org/10.1111/imj.13813CrossRefPubMed

29.

Sun M, Cheng J, Zhang Y, Wang F, Meng Y, Fu X (2016) Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma. J Magn Reson Imaging 44:1522–1529. https://doi.org/10.1002/jmri.25300CrossRefPubMed

30.

Albano D, Patti C, Sconfienza LM, Galia M (2017) Whole-body MRI in the early detection of multifocal osteonecrosis. Br J Radiol 90:20170240. https://doi.org/10.1259/bjr.20170280CrossRefPubMedPubMedCentral

31.

Chantry A, Kazmi M, Barrington S et al (2017) Guidelines for the use of imaging in the management of patients with myeloma. Br J Haematol 178:380–393. https://doi.org/10.1111/bjh.14827CrossRefPubMed

32.

Oxford Centre for Evidence-based Medicine (2009) Levels of evidence (March 2009). https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/. Accessed 4 Aug 2019

33.

Lecouvet FE, Talbot JN, Messiou C et al (2014) Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 50:2519–2531. https://doi.org/10.1016/j.ejca.2014.07.002CrossRefPubMed

34.

Schmidt GP, Wintersperger B, Graser A, Baur-Melnyk A, Reiser MF, Schoenberg SO (2007) High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol 42:449–459. https://doi.org/10.1097/01.rli.0000262089.55618.18CrossRefPubMed

35.

Schmidt GP, Baur-Melnyk A, Haug A et al (2008) Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT. Eur J Radiol 65:47–58. https://doi.org/10.1016/j.ejrad.2007.10.021CrossRefPubMed

36.

Schmidt GP, Baur-Melnyk A, Haug A et al (2009) Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 19:1366–1378. https://doi.org/10.1007/s00330-008-1289-yCrossRefPubMed

37.

Azzedine B, Kahina MB, Dimitri P, Christophe P, Alain D, Claude M (2015) Whole-body diffusion-weighted MRI for staging lymphoma at 3.0T: comparative study with MR imaging at 1.5T. Clin Imaging 39:104–109. https://doi.org/10.1016/j.clinimag.2014.06.017CrossRefPubMed

38.

Chavhan GB, Babyn PS (2011) Whole-body MR imaging in children: principles, technique, current applications, and future directions. Radiographics 31:1757–1772. https://doi.org/10.1148/rg.316115523CrossRefPubMed

39.

Punwani S, Cheung KK, Skipper N et al (2013) Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease. Pediatr Radiol 43:941–949. https://doi.org/10.1007/s00247-012-2616-7CrossRefPubMed

40.

Doniselli FM, Albano D, Chianca V, Cimmino MA, Sconfienza LM (2017) Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know. Clin Rheumatol 36:977–980. https://doi.org/10.1007/s10067-017-3604-yCrossRefPubMed

41.

Savarino E, Chianca V, Bodini G et al (2017) Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: which implications in patients with Crohn’s disease? Dig Liver Dis 49:728–730. https://doi.org/10.1016/j.dld.2017.04.010CrossRefPubMed

42.

Takahara T, Imai Y, Yamashita T et al (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275–282PubMed

43.

Attariwala R, Picker W (2013) Whole body MRI: improved lesion detection and characterization with diffusion weighted techniques. J Magn Reson Imaging 38:253–268. https://doi.org/10.1002/jmri.24285CrossRefPubMedPubMedCentral

44.

Morone M, Bali MA, Tunariu N et al (2017) Whole-body MRI: current applications in oncology. AJR Am J Roentgenol 209:W336–W349. https://doi.org/10.2214/AJR.17.17984CrossRefPubMed

45.

Albano D, Bruno A, Patti C et al (2020) Whole body magnetic resonance imaging (WB-MRI) in lymphoma: state of the art. Hematol Oncol 38:12–21. https://doi.org/10.1002/hon.2676CrossRefPubMed

Titel: Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey
verfasst von: Domenico Albano
Alessandro Stecco
Giuseppe Micci
Luca Maria Sconfienza
Stefano Colagrande
Alfonso Reginelli
Roberto Grassi
Alessandro Carriero
Massimo Midiri
Roberto Lagalla
Massimo Galia
Publikationsdatum: 01.02.2021
Verlag: Springer Milan
Erschienen in: La radiologia medica / Ausgabe 2/2021
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI: https://doi.org/10.1007/s11547-020-01242-7

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Whole-body magnetic resonance imaging (WB-MRI) in oncology: an Italian survey